The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results

Rhea-AI Summary

The Joint Corp. (NASDAQ: JYNT) reported Q4 and full-year 2024 financial results, showing continued growth despite transition challenges. Revenue increased 14% to $14.4M in Q4 2024 and 10% to $51.9M for the full year. The company achieved system-wide sales growth of 9% reaching $530.3M in 2024.

Key operational highlights include 14.7M patient visits and treatment of 957,000 new patients in 2024. The clinic network expanded to 967 total locations, with 842 franchised and 125 company-owned clinics. For 2025, guidance projects system-wide sales between $550-570M, mid-single-digit comp sales growth, and consolidated Adjusted EBITDA of $10.0-11.5M.

The company is transitioning to a pure-play franchisor model, with plans to refranchise corporate clinics and focus on strengthening core operations, revenue management, and digital marketing initiatives.

Positive

• Revenue growth of 14% in Q4 2024 and 10% for full-year
• System-wide sales increased 9% to $530.3M in 2024
• Patient visits grew to 14.7M in 2024 from 13.6M in 2023
• Total clinic count expanded to 967, up from 935 in 2023
• Strong cash position with $25.1M in unrestricted cash, up from $18.2M in 2023

Negative

• Net loss of $8.5M for full-year 2024
• Franchise license sales declined to 46 in 2024 from 55 in 2023
• Adjusted EBITDA decreased to $11.4M in 2024 from $12.2M in 2023
• Expected slowdown in new clinic openings for 2025 (30-40) compared to 57 in 2024
• 25 clinic closures in 2024 (including relocations)

Insights

Financial Analyst

The Joint Corp.'s Q4 and full-year 2024 results show meaningful financial improvement despite ongoing strategic transitions. The 14% quarterly revenue growth to $14.4 million and 10% annual revenue increase to $51.9 million demonstrate strong top-line momentum. Most impressive is the dramatic improvement in Q4 net income from continuing operations, which reached $986,000 compared to a $10.2 million loss in Q4 2023.

System-wide sales growth of 9% for both Q4 and full-year signals healthy franchise performance, with Q4's 6% comp sales acceleration from 4% in Q3 suggesting improving unit economics. The company added 32 net new clinics during 2024, expanding to 967 total locations while maintaining disciplined growth.

The strategic shift to a pure franchisor model represents a fundamental business transformation. While 2025 will be transitional with expected franchise openings slowing to 30-40 (vs. 57 in 2024), this approach should ultimately improve operating leverage and capital efficiency. The $25.1 million cash position provides ample liquidity for this transition.

The $8.5 million full-year net loss warrants monitoring, though it's an improvement from 2023's $9.8 million loss. Investors should note the $7.0 million loss from discontinued operations represents the corporate clinic segment being refranchised, which aligns with the strategic pivot.

Management's guidance suggests continued growth with system-wide sales projected between $550-570 million for 2025, representing 4-7% growth. The mid-single-digit comp sales guidance indicates confidence in clinic-level performance despite macroeconomic challenges.

Business Strategy Expert

The Joint's pivot to a pure-play franchisor model represents a significant strategic realignment that fundamentally changes its risk-reward profile. By divesting company-owned clinics through refranchising, management is executing a capital-light transformation similar to what we've seen succeed in other franchise systems like Denny's and Jack in the Box.

This transition eliminates the operational inconsistency that plagued the business—the $7.0 million loss from discontinued operations highlights how corporate locations were dragging down otherwise solid franchise performance. The franchise model brings higher-margin, more predictable royalty revenue streams that should translate to improved valuation multiples longer-term.

Three strategic initiatives warrant attention: First, the company's emphasis on dynamic revenue management indicates it's focusing on optimizing the revenue model beyond just unit growth. Second, the enhanced digital marketing approach addresses the critical patient acquisition funnel. Third, upgraded patient-facing technology acknowledges the importance of modernizing the customer experience in healthcare.

The 9% system-wide sales growth demonstrates the core concept remains attractive despite inflationary pressures impacting discretionary healthcare spending. With $25.1 million in cash and access to a $20 million credit facility, the company has sufficient capital to execute its transformation while investing in technology and marketing innovations.

While 2025 represents a transition year with tempered growth expectations, management's explicit confidence in accelerating performance in 2026 suggests a disciplined, multi-year strategic roadmap rather than short-term fixes.

03/13/2025 - 04:05 PM

- Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 -
- Increased system-wide sales 9% for both the year and Q4 2024 –

SCOTTSDALE, Ariz., March 13, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended December 31, 2024. The results of operations of the corporate clinics business segment have been classified as discontinued operations for all periods presented, and the following figures represent continuing operations unless otherwise stated.

Q4 2024 Financial Highlights

• Grew revenue to $14.4 million, up 14% compared to Q4 2023.
• Reported net income from continuing operations of $986,000, compared to net loss from continuing operations of $10.2 million, which included income tax expense of $11.2 million primarily to establish the valuation allowance against the company's deferred tax assets related to continuing operations, in Q4 2023.
• Increased system-wide sales¹ 9% to $145.2 million.
• Reported system-wide comp sales² of 6%, up from 4% in Q3 2024.
• Adjusted EBITDA is as follows:
  
  

$ in millions	From Continuing Operations	From Discontinued Operations	Consolidated Operations		From Continuing Operations	From Discontinued Operations	Consolidated Operations
	Q4 2024				Q4 2023
Adjusted EBITDA	$2.1	$1.2	$3.3		$2.2	$1.8	$4.0

President and Chief Executive Officer of The Joint Corp. Sanjiv Razdan, said, “In 2025, we are focused on bolstering our position as the leading chiropractic care provider, becoming a world class, pure play franchisor. We have begun executing initiatives to strengthen our core, reignite growth and improve both clinic and company level profitability. Already, in the fourth quarter of 2024, we have growing momentum with system-wide sales increasing 9%, compared to the fourth quarter of 2023.

“Looking ahead, 2025 will be a year in transition. Refranchising will reduce revenue and corresponding expense as well as lower our overhead and increase our operating leverage. Today, the majority of our corporate portfolio is in final stages to sign Letters of Intent for refranchising, and some existing franchisees are planning to invest in more clinics, validating our strategic growth plan. To drive revenue growth, we will initiate dynamic revenue management, enhance our digital marketing and promotional calendar, and upgrade our patient facing technology. Increasing our organizational agility and innovation, in 2025, we will begin building infrastructure and testing elements to capture new markets and revenue channels.

_____________________________________

¹ System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. 
² System-wide comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

“As the category leader with a premier national brand, attractive asset-light franchise model and extensive white space in the market, we have significant opportunities. Driving success, in 2026, we expect to grow net new clinic openings, system-wide sales, comp sales and Adjusted EBITDA. I am confident we will emerge as a stronger company.”

2024 Annual Financial Highlights

• Grew revenue to $51.9 million, up 10% compared to 2023.
• Reported net loss from continuing operations of $1.5 million compared to $10.8 million in 2023.
• Increased system-wide sales³ 9% to $530.3 million.
• Reported system-wide comp sales⁴ of 4%.
• Adjusted EBITDA is as follows:
  
  

$ in millions	From Continuing Operations	From Discontinued Operations	Consolidated Operations		From Continuing Operations	From Discontinued Operations	Consolidated Operations
	2024				2023
Adjusted EBITDA	$2.4	$9.0	$11.4		$4.5	$7.7	$12.2

2024 Full Year Operating Highlights

• Performed 14.7 million patient visits, compared to 13.6 million in 2023.
• Treated 957,000 new patients, compared to 932,000 in 2023.
• Increased system-wide sales³ 9%, compared to 12% in 2023.
• Delivered comp sales⁴ of 4% on par with 4% in 2023.
• Sold 46 franchise licenses, compared to 55 in 2023.
• Expanded total clinic count to 967, up from 935 clinics at December 31, 2023.
  • Opened 57, refranchised 3, and closed 18 (including 3 relocations) for a total of 842 franchised clinics at December 31, 2024, compared to 800 at December 31, 2023.
  • Refranchised 3 and closed 7 (including three non-traditional corporate units on Airforce bases) for a total of 125 company-owned or managed clinics at December 31, 2024, compared to 135 at December 31, 2023.

Financial Results for Fourth Quarter Ended Dec. 31, 2024 Compared to Dec. 31, 2023
Revenue increased 14% to $14.4 million in the fourth quarter of 2024, compared to $12.7 million in the fourth quarter of 2023. Cost of revenue was $3.2 million, compared to $2.8 million in the fourth quarter of 2023, reflecting the associated higher regional developer royalties and commissions.

Selling and marketing expenses were $2.7 million, compared to $1.7 million, reflecting the strategic decision to continue to support the recently started marketing campaign. Depreciation and amortization expenses increased 5% for the fourth quarter of 2024, as compared to the prior year period. General and administrative expenses were $7.2 million, up from $6.9 million in the fourth quarter of 2023.

Income tax expense was $37,000, compared to $11.2 million in the fourth quarter of 2023. Net income from continuing operations was $986,000, or $0.06 per diluted share, improving from a loss of $10.2 million dollars, or a loss of $0.69 per basic share, in the fourth quarter of 2023. Loss from discontinued operations was $3.7 million, or $0.25 per basic share, compared to $863,000, or $0.06 per basic share, in the fourth quarter of 2023. Net loss was $2.7 million, or $0.18 per basic share, improving from $11.0 million, or a loss of $0.75 per basic share in the fourth quarter of 2023.

_____________________________________

³ System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. 
⁴ System-wide comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

Adjusted EBITDA for continuing operations, discontinued operations and net operations were $2.1 million, $1.2 million and $3.3 million, respectively, compared to $2.2 million, $1.8 million and $4.0 million, respectively, in the fourth quarter of 2023.

Financial Results for Full Year 2024 Compared to Full Year 2023
Revenue was $51.9 million in 2024, up 10% compared to $47.0 million in 2023. Net loss from continuing operations was $1.5 million, or 10 cents per basic share, compared to $10.8 million, or 73 cents per basic share. Net loss from discontinued operations was $7.0 million, or 47 cents per basic share, compared to net income from discontinued operations of $1.0 million, or 7 cents per diluted share. Net loss was $8.5 million, or 57 cents per basic share, compared to $9.8 million, or 66 cents per basic share.

Adjusted EBITDA for continuing operations, discontinued operations and net operations were $2.4 million, $9.0 million and $11.4 million, respectively, compared to $4.5 million, $7.7 million and $12.2 million, respectively, in 2023.

Balance Sheet Liquidity
Unrestricted cash was $25.1 million at December 31, 2024, compared to $18.2 million at December 31, 2023. Cash flow for 2024 included $9.4 million from operations from both continuing and discontinued operations and the net proceeds of the sales of clinics offset by ongoing IT capex and the $2.0 million first quarter 2024 repayment of the line of credit to JP Morgan Chase. Through this facility, we have retained immediate access to $20 million through February 2027. As of December 31, 2024, the federal tax return net operating loss carryforward was $9.1 million.

2025 Guidance
The company provided the following guidance for 2025.

• System-wide sales are expected to be between $550 million and $570 million, compared to $530.3 million in 2024.
• System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits, compared to 4% in 2024.
• Consolidated Adjusted EBITDA is expected to be between $10.0 and $11.5 million, compared to $11.4 million in 2024. The 2025 Consolidated Adjusted EBITDA estimate includes an adjustment of $4.4 million related to, among other things, stock-based compensation and depreciation and amortization. The company will factor in any additional impairment or restructuring charges related to the refranchising should they occur.
• New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 30 and 40, compared to 57 in 2024.

Conference Call
The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, March 13, 2025, after the market close. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 1-(833) 630-0823 or (412) 317-1831 and ask to be joined into the ‘The Joint’ call approximately 15 minutes prior to the start time.

The live webcast of the call with accompanying slide presentation can be accessed in the IR events section https://ir.thejoint.com/events and available for approximately one year. An audio archive can be accessed for one week by dialing (877) 344-7529 or (412) 317-0088 and entering conference ID 6931921.

Commonly Discussed Performance Metrics
This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. System-wide comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

Non-GAAP Financial Information
This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Reconciliation of historical net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired regional developer rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business) and other income related to employee retention credits.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company’s financial statements filed with the SEC.

Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located at the end of this release. This release includes forward-looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the Company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward looking statements made in this press release include, among others, that in 2025, we are focused on bolstering our position as the leading chiropractic care provider, becoming a world-class, pure-play franchisor; our initiatives to strengthen our core, reignite growth and improve both clinic and company level profitability; our belief that refranchising will reduce our overhead and increase our operating leverage; our expectation that to drive revenue growth, we will initiate dynamic revenue management, enhance our digital marketing and promotional calendar, and catch up on patient facing technology; our belief that by increasing our organizational agility and innovation, in 2025, we will begin building infrastructure and testing elements to capture new markets and revenue channels; our belief that we have significant opportunities; our belief that by driving success, in 2026, we expect to grow net new clinic openings, system-wide sales, comp sales and Adjusted EBITDA; our confidence that we will emerge as a stronger company; and our 2025 guidance for system-wide sales, system-wide comp sales for all clinics open 13 months or more; Adjusted EBITDA, and new franchised clinic openings, excluding the impact of refranchised clinics. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, which has increased our costs and which could otherwise negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 8, 2024 and subsequently filed current and quarterly reports. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With over 950 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times’ annual “Top 400” and “Fast & Serious” list of 40 smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and is regularly ranked on the publication’s “Franchise 500,” the “Fastest-Growing Franchises,” the “Best of the Best” lists, as well as its “Top Franchise for Veterans” and “Top Brands for Multi-Unit Owners.” SUCCESS named the company as one of the “Top 50 Franchises” in 2024. The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Media Contact:
Margie Wojciechowski, The Joint Corp., margie.wojciechowski@thejoint.com  
Investor Contact:
Kirsten Chapman, Alliance Advisors IR, 415-433-3777, thejointinvestor@allianceadvisors.com

– Financial Tables Follow –

THE JOINT CORP.
CONSOLIDATED BALANCE SHEETS
	December 31, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	25,051,355			$	18,153,609
Restricted cash		945,081				1,060,683
Accounts receivable, net		2,586,381				2,580,589
Deferred franchise and regional development costs, current portion		1,055,582				1,047,430
Prepaid expenses and other current assets		1,729,079				1,844,340
Discontinued operations current assets ($1.1 million attributable to VIEs as of December 31, 2024)		40,827,044				19,648,887
Total current assets		72,194,522				44,335,538
Property and equipment, net		3,166,882				3,805,887
Operating lease right-of-use asset		245,384				466,268
Deferred franchise and regional development costs, net of current portion		4,513,891				5,203,936
Discontinued operations noncurrent assets ($1.1 million attributable to VIEs as of December 31, 2023)		—				33,142,084
Deposits and other assets		300,779				254,299
Total assets	$	80,421,458			$	87,208,012
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	1,750,938			$	1,253,816
Accrued expenses		1,505,827				1,157,822
Co-op funds liability		945,082				1,060,683
Payroll liabilities		3,551,173				858,862
Operating lease liability, current portion		448,285				412,601
Deferred franchise fee revenue, current portion		2,546,926				2,516,554
Upfront regional developer fees, current portion		288,095				362,326
Other current liabilities		603,250				483,249
Discontinued operations current liabilities ($7.1 million and $5.9 million attributable to VIEs as of December 31, 2024 and 2023)		37,714,200				25,468,169
Total current liabilities		49,353,776				33,574,082
Operating lease liability, net of current portion		—				448,308
Debt under the Credit Agreement		—				2,000,000
Deferred franchise fee revenue, net of current portion		12,450,179				13,597,325
Upfront regional developer fees, net of current portion		672,334				1,019,316
Discontinued operations liabilities, net of current portion ($1.2 million attributable to VIEs as of December 31, 2023)		—				11,739,946
Deferred tax liabilities		—				57,153
Total liabilities		62,476,289				62,436,130
Commitments and contingencies (Note 9)
Stockholders’ equity:
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of December 31, 2024 and 2023		—				—
Common stock, $0.001 par value; 20,000,000 shares authorized, 15,192,893 shares issued and 15,159,878 shares outstanding as of December 31, 2024 and 14,783,757 shares issued and 14,751,633 outstanding as of December 31, 2023		15,192				14,783
Additional paid-in capital		49,210,455				47,498,151
Treasury stock 33,015 shares as of December 31, 2024 and 32,124 shares as of December 31, 2023, at cost		(870,058	)			(860,475	)
Accumulated deficit		(30,435,420	)			(21,905,577	)
Total The Joint Corp. stockholders’ equity		17,920,169				24,746,882
Non-controlling Interest		25,000				25,000
Total equity		17,945,169				24,771,882
Total liabilities and stockholders’ equity	$	80,421,458			$	87,208,012

THE JOINT CORP.
CONSOLIDATED INCOME STATEMENTS
	Three Months Ended December 31,								Year Ended December 31,
	2024				2023				2024				2023
Revenues:
Royalty fees	$	8,840,890			$	7,978,859			$	32,144,796			$	29,160,832
Franchise fees		925,184				703,072				2,997,850				2,882,895
Advertising fund revenue		2,525,307				2,277,481				9,180,281				8,321,043
Software fees		1,454,193				1,340,168				5,687,326				5,086,562
Other revenues		701,883				409,121				1,886,352				1,526,145
Total revenues		14,447,457				12,708,701				51,896,605				46,977,477
Cost of revenues:
Franchise and regional developer cost of revenues		2,813,292				2,457,410				10,063,644				9,063,375
IT cost of revenues		371,499				382,577				1,453,011				1,417,270
Total cost of revenues		3,184,791				2,839,987				11,516,655				10,480,645
Selling and marketing expenses		2,741,200				1,663,768				10,923,342				8,689,664
Depreciation and amortization		345,530				329,919				1,363,453				1,278,148
General and administrative expenses		7,222,128				6,903,078				29,833,570				26,231,615
Total selling, general and administrative expenses		10,308,858				8,896,765				42,120,365				36,199,427
Net loss (gain) on disposition or impairment		10,124				(22,694	)			14,642				(20,894	)
(Loss) income from operations		943,684				994,643				(1,755,057	)			318,299
Other (income) loss, net		(79,729	)			(4,138	)			(280,287	)			64,293
(Loss) income before income tax expense		1,023,413				998,781				(1,474,770	)			254,006
Income tax expense		37,000				11,177,392				62,142				11,023,411
Net loss from continuing operations	$	986,413			$	(10,178,611	)		$	(1,536,912	)		$	(10,769,405	)
Discontinued Operations:
(Loss) income from discontinued operations before income tax expense		(3,883,748	)			(1,142,713	)			(6,780,289	)			1,384,750
Income tax expense from discontinued operations		(182,050	)			(279,725	)			212,642				367,542
Net (loss) income from discontinued operations	$	(3,701,698	)		$	(862,988	)		$	(6,992,931	)		$	1,017,208
Net (loss) income	$	(2,715,285	)		$	(11,041,599	)		$	(8,529,843	)		$	(9,752,197	)
Net loss from continuing operations per common share:
Basic	$	0.07			$	(0.69	)		$	(0.10	)		$	(0.73	)
Diluted	$	0.06			$	(0.68	)		$	(0.10	)		$	(0.72	)
Net (loss) income from discontinued operations per common share:
Basic	$	(0.25	)		$	(0.06	)		$	(0.47	)		$	0.07
Diluted	$	(0.24	)		$	(0.06	)		$	(0.46	)		$	0.07
Net loss per common share:
Basic	$	(0.18	)		$	(0.75	)		$	(0.57	)		$	(0.66	)
Diluted	$	(0.18	)		$	(0.74	)		$	(0.56	)		$	(0.65	)
Basic weighted average shares outstanding		14,964,854				14,753,079				14,919,091				14,688,115
Diluted weighted average shares outstanding		15,176,596				14,933,539				15,147,247				14,935,217

THE JOINT CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
	Year Ended December 31,
	2024				2023
Cash flows from operating activities:
Net loss	$	(8,529,843	)		$	(9,752,197	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		4,722,137				8,582,203
Net loss on disposition or impairment (non-cash portion)		10,454,609				2,632,604
Net franchise fees recognized upon termination of franchise agreements		(239,335	)			(217,827	)
Deferred income taxes		(55,556	)			10,896,504
Provision for credit losses on accounts receivable		220,893				—
Stock based compensation expense		1,679,005				1,737,682
Changes in operating assets and liabilities:
Accounts receivable		(1,645,078	)			192,348
Prepaid expenses and other current assets		160,082				(341,478	)
Deferred franchise costs		499,285				355,952
Deposits and other assets		8,827				1,492
Accounts payable		68,258				(1,381,836	)
Accrued expenses		4,609,759				793,679
Payroll liabilities		2,398,765				1,455,234
Operating lease liabilities		(3,796,648	)			(107,735	)
Upfront regional developer fees		(421,213	)			(598,778	)
Deferred revenue		(597,489	)			301,095
Other liabilities		(121,408	)			128,647
Net cash provided by operating activities		9,415,050				14,677,589
Cash flows from investing activities:
Acquisition of CA clinics		—				(1,188,765	)
Proceeds from sale of clinics		554,100				—
Purchase of property and equipment		(1,185,647	)			(4,999,070	)
Net cash used in investing activities		(631,547	)			(6,187,835	)
Cash flows from financing activities:
Payments of finance lease obligation		(25,484	)			(24,432	)
Purchases of treasury stock under employee stock plans		(9,583	)			(3,833	)
Proceeds from exercise of stock options		33,708				202,386
Repayment of debt under the Credit Agreement		(2,000,000	)			—
Net cash (used in) provided by financing activities		(2,001,359	)			174,121
Increase in cash		6,782,144				8,663,875
Cash, cash equivalents and restricted cash, beginning of period		19,214,292				10,550,417
Cash, cash equivalents and restricted cash, end of period	$	25,996,436			$	19,214,292
	December 31, 2024				December 31, 2023
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	25,051,355			$	18,153,609
Restricted cash		945,081				1,060,683
	$	25,996,436			$	19,214,292

THE JOINT CORP.
QUARTERLY FINANCIAL DATA - RECAST FOR DISCONTINUED OPERATIONS
(unaudited)
	2024													2023
	Q1			Q2			Q3			Q4				Q1			Q2			Q3			Q4
Total revenues	$	12,184,716		$	12,610,036		$	12,654,396		$	14,447,457			$	11,172,863		$	11,504,267		$	11,591,646		$	12,708,701
Total costs of revenues		2,704,512			2,812,389			2,814,963			3,184,791				2,464,319			2,584,772			2,591,567			2,839,987
Selling and marketing expenses		2,237,583			3,440,391			2,504,168			2,741,200				2,315,052			2,470,188			2,240,656			1,663,768
Depreciation and amortization		329,634			342,454			345,835			345,530				314,796			314,894			318,539			329,919
General and administrative expenses		7,339,308			7,793,465			7,478,669			7,222,128				6,336,586			6,547,337			6,444,614			6,903,078
Total selling, general and administrative expenses		9,906,525			11,576,310			10,328,672			10,308,858				8,966,434			9,332,419			9,003,809			8,896,765
Net loss (gain) on disposition or impairment		275			662			3,581			10,124				—			1,713			87			(22,694	)
(Loss) income from operations		(426,596	)		(1,779,325	)		(492,820	)		943,684				(257,890	)		(414,637	)		(3,817	)		994,643
Other (income) loss, net		(36,259	)		(80,471	)		(83,828	)		(79,729	)			(42,748	)		105,695			5,484			(4,138	)
(Loss) income before income tax expense		(390,337	)		(1,698,854	)		(408,992	)		1,023,413				(215,142	)		(520,332	)		(9,301	)		998,781
Income tax expense (benefit)		8,582			11,169			5,391			37,000				(42,187	)		(95,823	)		(15,971	)		11,177,392
Net income (loss) from continuing operations		(398,919	)		(1,710,023	)		(414,383	)		986,413				(172,955	)		(424,509	)		6,670			(10,178,611	)
Income (loss) from discontinued operations before income tax expense		1,516,243			(1,719,222	)		(2,693,562	)		(3,883,748	)			3,383,195			39,258			(894,990	)		(1,142,713	)
Income tax expense (benefit) from discontinued operations		170,345			167,153			57,194			(182,050	)			884,076			(64,762	)		(172,047	)		(279,725	)
Net income (loss) from discontinued operations		1,345,898			(1,886,375	)		(2,750,756	)		(3,701,698	)			2,499,119			104,020			(722,943	)		(862,988	)
Net income (loss)		946,979			(3,596,398	)		(3,165,139	)		(2,715,285	)			2,326,164			(320,489	)		(716,273	)		(11,041,599	)
Net income (loss) from continuing operations per common share
Basic	$	(0.03	)	$	(0.11	)	$	(0.03	)	$	0.07			$	(0.01	)	$	(0.03	)	$	0.00		$	(0.69	)
Diluted	$	(0.03	)	$	(0.11	)	$	(0.03	)	$	0.06			$	(0.01	)	$	(0.03	)	$	0.00		$	(0.68	)
Net income (loss) from discontinued operations per common share:
Basic	$	0.09		$	(0.13	)	$	(0.18	)	$	(0.25	)		$	0.17		$	0.01		$	(0.05	)	$	(0.06	)
Diluted	$	0.09		$	(0.12	)	$	(0.18	)	$	(0.24	)		$	0.17		$	0.01		$	(0.05	)	$	(0.06	)
Net income (loss) per common share:
Basic	$	0.06		$	(0.24	)	$	(0.21	)	$	(0.18	)		$	0.16		$	(0.02	)	$	(0.05	)	$	(0.75	)
Diluted	$	0.06		$	(0.24	)	$	(0.21	)	$	(0.18	)		$	0.16		$	(0.02	)	$	(0.05	)	$	(0.74	)

THE JOINT CORP.
CONSOLIDATED RECONCILIATION FROM GAAP TO NON-GAAP
(unaudited)
	Year Ended December 31,
	2024										2023
	from Continuing Operations			from Discontinued Operations			Consolidated Operations				from Continuing Operations			from Discontinued Operations			Consolidated Operations
Non-GAAP Financial Data:
(Loss) Income	$	(1,536,912	)	$	(6,992,931	)	$	(8,529,843	)		$	(10,769,405	)	$	1,017,208		$	(9,752,197	)
Net interest		(280,287	)		2,114			(278,173	)			64,293			3,168			67,461
Depreciation and amortization expense		1,363,453			3,358,684			4,722,137				1,278,148			7,304,055			8,582,203
Income tax expense		62,142			212,642			274,784				11,023,411			367,542			11,390,953
EBITDA		(391,604	)		(3,419,491	)		(3,811,095	)			1,596,447			8,691,973			10,288,420
Stock compensation expense		1,679,005			—			1,679,005				1,737,682			—			1,737,682
Acquisition related expenses		478,710			—			478,710				811,547			61,667			873,214
Net loss on disposition or impairment		14,642			10,439,967			10,454,609				(20,894	)		2,653,498			2,632,604
Costs related to restatement filings		—			—			—				380,221			—			380,221
Restructuring Costs		607,231			495,097			1,102,328				—			72,880			72,880
Litigation expenses		—			1,481,000			1,481,000				—			—			—
Other income related to the ERC		—			—			—				—			(3,779,304	)		(3,779,304	)
Adjusted EBITDA	$	2,387,984		$	8,996,573		$	11,384,557			$	4,505,003		$	7,700,714		$	12,205,717

	Three Months Ended December 31,
	2024										2023
	from Continuing Operations			from Discontinued Operations			Consolidated Operations				from Continuing Operations			from Discontinued Operations			Consolidated Operations
Non-GAAP Financial Data:
(Loss) Income	$	986,413		$	(3,701,698	)	$	(2,715,285	)		$	(10,178,611	)	$	(862,988	)	$	(11,041,599	)
Net interest		(79,729	)		429			(79,300	)			(4,140	)		695			(3,445	)
Depreciation and amortization expense		345,530			209,655			555,185				329,919			1,358,756			1,688,675
Income tax expense		37,000			(182,050	)		(145,050	)			11,177,392			(279,725	)		10,897,667
EBITDA		1,289,214			(3,673,664	)		(2,384,450	)			1,324,560			216,738			1,541,298
Stock compensation expense		203,295			—			203,295				528,386			—			528,386
Net loss on disposition or impairment		10,124			4,841,844			4,851,968				(22,694	)		1,540,561			1,517,867
Costs related to restatement filings		—			—			—				380,221			—			380,221
Restructuring Costs		579,231			68,640			647,871				—			72,880			72,880
Adjusted EBITDA	$	2,081,864		$	1,236,820		$	3,318,684			$	2,210,473		$	1,830,179		$	4,040,652

FAQ

What were The Joint Corp's (JYNT) Q4 2024 revenue and growth figures?

JYNT reported Q4 2024 revenue of $14.4M, up 14% compared to Q4 2023, with system-wide sales increasing 9% to $145.2M.

How many clinics did The Joint Corp (JYNT) operate as of December 31, 2024?

The Joint Corp operated 967 total clinics, consisting of 842 franchised locations and 125 company-owned or managed clinics.

What is The Joint Corp's (JYNT) system-wide sales guidance for 2025?

JYNT expects system-wide sales between $550-570M in 2025, compared to $530.3M in 2024.

How many new franchise licenses did The Joint Corp (JYNT) sell in 2024?

The Joint Corp sold 46 franchise licenses in 2024, compared to 55 in 2023.

What was The Joint Corp's (JYNT) patient visit growth in 2024?

JYNT performed 14.7M patient visits in 2024, up from 13.6M in 2023, and treated 957,000 new patients.